nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2B6—Thiotepa—urinary bladder cancer	0.188	0.296	CbGbCtD
Nevirapine—CYP2A6—Fluorouracil—urinary bladder cancer	0.0937	0.148	CbGbCtD
Nevirapine—CYP3A4—Thiotepa—urinary bladder cancer	0.0577	0.091	CbGbCtD
Nevirapine—CYP2B6—Cisplatin—urinary bladder cancer	0.0518	0.0817	CbGbCtD
Nevirapine—CYP3A5—Etoposide—urinary bladder cancer	0.0401	0.0632	CbGbCtD
Nevirapine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0358	0.0564	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0347	0.0548	CbGbCtD
Nevirapine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0322	0.0508	CbGbCtD
Nevirapine—CYP1A2—Etoposide—urinary bladder cancer	0.0299	0.0471	CbGbCtD
Nevirapine—CYP2C9—Cisplatin—urinary bladder cancer	0.0274	0.0432	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0168	0.0265	CbGbCtD
Nevirapine—CYP3A4—Etoposide—urinary bladder cancer	0.0156	0.0247	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0107	0.0168	CbGbCtD
Nevirapine—CYP1A2—urine—urinary bladder cancer	0.00305	0.135	CbGeAlD
Nevirapine—CYP2C9—urine—urinary bladder cancer	0.00289	0.128	CbGeAlD
Nevirapine—CYP3A4—urine—urinary bladder cancer	0.00221	0.0979	CbGeAlD
Nevirapine—CYP2D6—urine—urinary bladder cancer	0.00217	0.0963	CbGeAlD
Nevirapine—CYP2A6—prostate gland—urinary bladder cancer	0.00208	0.0924	CbGeAlD
Nevirapine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00176	0.0782	CbGeAlD
Nevirapine—CYP3A5—prostate gland—urinary bladder cancer	0.00106	0.0468	CbGeAlD
Nevirapine—CYP2A6—vagina—urinary bladder cancer	0.00103	0.0456	CbGeAlD
Nevirapine—CYP1A2—renal system—urinary bladder cancer	0.000746	0.0331	CbGeAlD
Nevirapine—CYP3A5—renal system—urinary bladder cancer	0.000719	0.0319	CbGeAlD
Nevirapine—CYP2B6—renal system—urinary bladder cancer	0.000715	0.0317	CbGeAlD
Nevirapine—CYP2B6—female reproductive system—urinary bladder cancer	0.000572	0.0254	CbGeAlD
Nevirapine—CYP2C9—female reproductive system—urinary bladder cancer	0.000567	0.0252	CbGeAlD
Nevirapine—CYP3A4—renal system—urinary bladder cancer	0.00054	0.024	CbGeAlD
Nevirapine—CYP2D6—renal system—urinary bladder cancer	0.000531	0.0236	CbGeAlD
Nevirapine—CYP3A5—vagina—urinary bladder cancer	0.000521	0.0231	CbGeAlD
Nevirapine—CYP2B6—vagina—urinary bladder cancer	0.000518	0.023	CbGeAlD
Nevirapine—CYP3A4—female reproductive system—urinary bladder cancer	0.000432	0.0192	CbGeAlD
Nevirapine—CYP2D6—female reproductive system—urinary bladder cancer	0.000425	0.0189	CbGeAlD
Nevirapine—Malaise—Etoposide—urinary bladder cancer	0.000346	0.00151	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000346	0.0015	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—urinary bladder cancer	0.000345	0.0015	CcSEcCtD
Nevirapine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000345	0.0015	CcSEcCtD
Nevirapine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000345	0.0015	CcSEcCtD
Nevirapine—Anorexia—Fluorouracil—urinary bladder cancer	0.000344	0.00149	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000344	0.00149	CcSEcCtD
Nevirapine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000342	0.00149	CcSEcCtD
Nevirapine—Oedema—Cisplatin—urinary bladder cancer	0.000342	0.00149	CcSEcCtD
Nevirapine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000335	0.00146	CcSEcCtD
Nevirapine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000335	0.00146	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000334	0.00145	CcSEcCtD
Nevirapine—Skin disorder—Cisplatin—urinary bladder cancer	0.000332	0.00144	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.00033	0.00143	CcSEcCtD
Nevirapine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00033	0.00143	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000329	0.00143	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—urinary bladder cancer	0.000327	0.00142	CcSEcCtD
Nevirapine—Somnolence—Gemcitabine—urinary bladder cancer	0.000326	0.00142	CcSEcCtD
Nevirapine—Anorexia—Cisplatin—urinary bladder cancer	0.000326	0.00142	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000325	0.00141	CcSEcCtD
Nevirapine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000324	0.00141	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—urinary bladder cancer	0.000324	0.00141	CcSEcCtD
Nevirapine—Discomfort—Etoposide—urinary bladder cancer	0.000323	0.0014	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000322	0.0014	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000322	0.0014	CcSEcCtD
Nevirapine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000321	0.0014	CcSEcCtD
Nevirapine—Somnolence—Fluorouracil—urinary bladder cancer	0.000321	0.00139	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—urinary bladder cancer	0.000319	0.00139	CcSEcCtD
Nevirapine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000319	0.00139	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000317	0.00138	CcSEcCtD
Nevirapine—Fatigue—Gemcitabine—urinary bladder cancer	0.000316	0.00138	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000315	0.00137	CcSEcCtD
Nevirapine—Pain—Gemcitabine—urinary bladder cancer	0.000314	0.00136	CcSEcCtD
Nevirapine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000314	0.00136	CcSEcCtD
Nevirapine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000313	0.00136	CcSEcCtD
Nevirapine—Asthenia—Thiotepa—urinary bladder cancer	0.000313	0.00136	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000312	0.00135	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000311	0.00135	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—urinary bladder cancer	0.000309	0.00134	CcSEcCtD
Nevirapine—Pruritus—Thiotepa—urinary bladder cancer	0.000309	0.00134	CcSEcCtD
Nevirapine—Pain—Fluorouracil—urinary bladder cancer	0.000309	0.00134	CcSEcCtD
Nevirapine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000307	0.00134	CcSEcCtD
Nevirapine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000307	0.00133	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000306	0.00133	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000305	0.00133	CcSEcCtD
Nevirapine—Skin disorder—Etoposide—urinary bladder cancer	0.000304	0.00132	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—urinary bladder cancer	0.000303	0.00132	CcSEcCtD
Nevirapine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000302	0.00131	CcSEcCtD
Nevirapine—Anorexia—Etoposide—urinary bladder cancer	0.000299	0.0013	CcSEcCtD
Nevirapine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000298	0.0013	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000298	0.00129	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000298	0.00129	CcSEcCtD
Nevirapine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000297	0.00129	CcSEcCtD
Nevirapine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000297	0.00129	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000295	0.00128	CcSEcCtD
Nevirapine—Pain—Cisplatin—urinary bladder cancer	0.000292	0.00127	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000292	0.00127	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000292	0.00127	CcSEcCtD
Nevirapine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00029	0.00126	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—urinary bladder cancer	0.000289	0.00126	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—urinary bladder cancer	0.000289	0.00126	CcSEcCtD
Nevirapine—Urticaria—Fluorouracil—urinary bladder cancer	0.000287	0.00125	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000286	0.00124	CcSEcCtD
Nevirapine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000285	0.00124	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000283	0.00123	CcSEcCtD
Nevirapine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000282	0.00123	CcSEcCtD
Nevirapine—Paraesthesia—Etoposide—urinary bladder cancer	0.000281	0.00122	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00028	0.00122	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000279	0.00121	CcSEcCtD
Nevirapine—Somnolence—Etoposide—urinary bladder cancer	0.000279	0.00121	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000278	0.00121	CcSEcCtD
Nevirapine—Vomiting—Thiotepa—urinary bladder cancer	0.000277	0.00121	CcSEcCtD
Nevirapine—Rash—Thiotepa—urinary bladder cancer	0.000275	0.0012	CcSEcCtD
Nevirapine—Dermatitis—Thiotepa—urinary bladder cancer	0.000275	0.00119	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000275	0.00119	CcSEcCtD
Nevirapine—Headache—Thiotepa—urinary bladder cancer	0.000273	0.00119	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000273	0.00119	CcSEcCtD
Nevirapine—Decreased appetite—Etoposide—urinary bladder cancer	0.000272	0.00118	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—urinary bladder cancer	0.000271	0.00118	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000271	0.00118	CcSEcCtD
Nevirapine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00027	0.00118	CcSEcCtD
Nevirapine—Fatigue—Etoposide—urinary bladder cancer	0.00027	0.00117	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00027	0.00117	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—urinary bladder cancer	0.000268	0.00117	CcSEcCtD
Nevirapine—Pain—Etoposide—urinary bladder cancer	0.000268	0.00116	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000268	0.00116	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—urinary bladder cancer	0.000267	0.00116	CcSEcCtD
Nevirapine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000266	0.00116	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—urinary bladder cancer	0.000264	0.00115	CcSEcCtD
Nevirapine—Asthenia—Gemcitabine—urinary bladder cancer	0.000263	0.00114	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00026	0.00113	CcSEcCtD
Nevirapine—Pruritus—Gemcitabine—urinary bladder cancer	0.00026	0.00113	CcSEcCtD
Nevirapine—Nausea—Thiotepa—urinary bladder cancer	0.000259	0.00113	CcSEcCtD
Nevirapine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000258	0.00112	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000258	0.00112	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000257	0.00112	CcSEcCtD
Nevirapine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000256	0.00111	CcSEcCtD
Nevirapine—Pruritus—Fluorouracil—urinary bladder cancer	0.000255	0.00111	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000253	0.0011	CcSEcCtD
Nevirapine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000252	0.0011	CcSEcCtD
Nevirapine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000251	0.00109	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—urinary bladder cancer	0.00025	0.00109	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00025	0.00109	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.00025	0.00109	CcSEcCtD
Nevirapine—Urticaria—Etoposide—urinary bladder cancer	0.000249	0.00108	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—urinary bladder cancer	0.000248	0.00108	CcSEcCtD
Nevirapine—Body temperature increased—Etoposide—urinary bladder cancer	0.000248	0.00108	CcSEcCtD
Nevirapine—Abdominal pain—Etoposide—urinary bladder cancer	0.000248	0.00108	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000248	0.00108	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—urinary bladder cancer	0.000247	0.00107	CcSEcCtD
Nevirapine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000247	0.00107	CcSEcCtD
Nevirapine—Asthenia—Cisplatin—urinary bladder cancer	0.000245	0.00107	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000243	0.00106	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000241	0.00105	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000239	0.00104	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000238	0.00103	CcSEcCtD
Nevirapine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000234	0.00102	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000234	0.00102	CcSEcCtD
Nevirapine—Vomiting—Gemcitabine—urinary bladder cancer	0.000233	0.00101	CcSEcCtD
Nevirapine—Rash—Gemcitabine—urinary bladder cancer	0.000231	0.00101	CcSEcCtD
Nevirapine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000231	0.001	CcSEcCtD
Nevirapine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000231	0.001	CcSEcCtD
Nevirapine—Erythema—Methotrexate—urinary bladder cancer	0.00023	0.001	CcSEcCtD
Nevirapine—Headache—Gemcitabine—urinary bladder cancer	0.00023	0.000999	CcSEcCtD
Nevirapine—Vomiting—Fluorouracil—urinary bladder cancer	0.000229	0.000997	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000229	0.000994	CcSEcCtD
Nevirapine—Rash—Fluorouracil—urinary bladder cancer	0.000227	0.000989	CcSEcCtD
Nevirapine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000227	0.000988	CcSEcCtD
Nevirapine—Headache—Fluorouracil—urinary bladder cancer	0.000226	0.000983	CcSEcCtD
Nevirapine—Asthenia—Etoposide—urinary bladder cancer	0.000225	0.000977	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000225	0.000977	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000223	0.000971	CcSEcCtD
Nevirapine—Pruritus—Etoposide—urinary bladder cancer	0.000222	0.000964	CcSEcCtD
Nevirapine—Nausea—Gemcitabine—urinary bladder cancer	0.000218	0.000947	CcSEcCtD
Nevirapine—Vomiting—Cisplatin—urinary bladder cancer	0.000217	0.000945	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000216	0.00094	CcSEcCtD
Nevirapine—Rash—Cisplatin—urinary bladder cancer	0.000216	0.000937	CcSEcCtD
Nevirapine—Dermatitis—Cisplatin—urinary bladder cancer	0.000215	0.000937	CcSEcCtD
Nevirapine—Erythema—Epirubicin—urinary bladder cancer	0.000215	0.000936	CcSEcCtD
Nevirapine—Diarrhoea—Etoposide—urinary bladder cancer	0.000214	0.000932	CcSEcCtD
Nevirapine—Nausea—Fluorouracil—urinary bladder cancer	0.000214	0.000932	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000213	0.000928	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—urinary bladder cancer	0.000213	0.000924	CcSEcCtD
Nevirapine—Malaise—Methotrexate—urinary bladder cancer	0.000207	0.000901	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000207	0.000898	CcSEcCtD
Nevirapine—Nausea—Cisplatin—urinary bladder cancer	0.000203	0.000883	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0002	0.000868	CcSEcCtD
Nevirapine—Vomiting—Etoposide—urinary bladder cancer	0.000199	0.000866	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—urinary bladder cancer	0.000199	0.000866	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—urinary bladder cancer	0.000199	0.000865	CcSEcCtD
Nevirapine—Rash—Etoposide—urinary bladder cancer	0.000198	0.000859	CcSEcCtD
Nevirapine—Dermatitis—Etoposide—urinary bladder cancer	0.000197	0.000858	CcSEcCtD
Nevirapine—Headache—Etoposide—urinary bladder cancer	0.000196	0.000853	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—urinary bladder cancer	0.000196	0.000851	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—urinary bladder cancer	0.000196	0.000851	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000194	0.000845	CcSEcCtD
Nevirapine—Malaise—Epirubicin—urinary bladder cancer	0.000194	0.000844	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—urinary bladder cancer	0.000193	0.000841	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000188	0.000816	CcSEcCtD
Nevirapine—Nausea—Etoposide—urinary bladder cancer	0.000186	0.000809	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000185	0.000803	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000184	0.0008	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—urinary bladder cancer	0.000184	0.0008	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000184	0.000799	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—urinary bladder cancer	0.000183	0.000796	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—urinary bladder cancer	0.000183	0.000796	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—urinary bladder cancer	0.000182	0.000792	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000182	0.000791	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—urinary bladder cancer	0.000181	0.000787	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—urinary bladder cancer	0.00018	0.000781	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—urinary bladder cancer	0.000179	0.000778	CcSEcCtD
Nevirapine—Oedema—Epirubicin—urinary bladder cancer	0.000176	0.000764	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000176	0.000764	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000172	0.000749	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000172	0.000748	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000171	0.000743	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—urinary bladder cancer	0.000171	0.000742	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—urinary bladder cancer	0.00017	0.000737	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—urinary bladder cancer	0.00017	0.000737	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000169	0.000733	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000168	0.000732	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—urinary bladder cancer	0.000168	0.000728	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—urinary bladder cancer	0.000167	0.000728	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—urinary bladder cancer	0.000167	0.000725	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000163	0.000709	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000163	0.000706	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—urinary bladder cancer	0.000163	0.000706	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000162	0.000704	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—urinary bladder cancer	0.000162	0.000703	CcSEcCtD
Nevirapine—Pain—Methotrexate—urinary bladder cancer	0.000161	0.000698	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00016	0.000696	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000159	0.000693	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000159	0.000692	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000686	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000158	0.000686	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—urinary bladder cancer	0.000156	0.000679	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—urinary bladder cancer	0.000155	0.000673	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000155	0.000672	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000153	0.000667	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000153	0.000664	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000152	0.000659	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—urinary bladder cancer	0.000151	0.000658	CcSEcCtD
Nevirapine—Pain—Epirubicin—urinary bladder cancer	0.00015	0.000653	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—urinary bladder cancer	0.000149	0.000648	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000148	0.000645	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000148	0.000645	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000148	0.000644	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000146	0.000634	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000145	0.000629	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—urinary bladder cancer	0.000144	0.000628	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000144	0.000624	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000141	0.000614	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00014	0.00061	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—urinary bladder cancer	0.00014	0.000609	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—urinary bladder cancer	0.00014	0.000607	CcSEcCtD
Nevirapine—Pain—Doxorubicin—urinary bladder cancer	0.000139	0.000604	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000139	0.000604	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000139	0.000604	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000138	0.000601	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000138	0.00122	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000137	0.00121	CbGpPWpGaD
Nevirapine—CYP2B6—Biological oxidations—GSTP1—urinary bladder cancer	0.000137	0.00121	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000136	0.0012	CbGpPWpGaD
Nevirapine—CYP2B6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000135	0.00119	CbGpPWpGaD
Nevirapine—Asthenia—Methotrexate—urinary bladder cancer	0.000135	0.000585	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000134	0.000582	CcSEcCtD
Nevirapine—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000134	0.00118	CbGpPWpGaD
Nevirapine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000578	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—urinary bladder cancer	0.000133	0.000577	CcSEcCtD
Nevirapine—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000132	0.00116	CbGpPWpGaD
Nevirapine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000131	0.00116	CbGpPWpGaD
Nevirapine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000129	0.000563	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—urinary bladder cancer	0.000129	0.000561	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000128	0.000558	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000128	0.000558	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000128	0.000558	CcSEcCtD
Nevirapine—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000126	0.00112	CbGpPWpGaD
Nevirapine—Asthenia—Epirubicin—urinary bladder cancer	0.000126	0.000548	CcSEcCtD
Nevirapine—CYP2B6—Biological oxidations—GSTM1—urinary bladder cancer	0.000126	0.00111	CbGpPWpGaD
Nevirapine—Pruritus—Epirubicin—urinary bladder cancer	0.000124	0.00054	CcSEcCtD
Nevirapine—CYP2B6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000124	0.0011	CbGpPWpGaD
Nevirapine—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000123	0.00109	CbGpPWpGaD
Nevirapine—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000121	0.00107	CbGpPWpGaD
Nevirapine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00012	0.000522	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00012	0.00106	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.00012	0.00106	CbGpPWpGaD
Nevirapine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00012	0.00052	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—urinary bladder cancer	0.000119	0.000519	CcSEcCtD
Nevirapine—Rash—Methotrexate—urinary bladder cancer	0.000118	0.000514	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—urinary bladder cancer	0.000118	0.000514	CcSEcCtD
Nevirapine—Headache—Methotrexate—urinary bladder cancer	0.000118	0.000511	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—urinary bladder cancer	0.000117	0.000507	CcSEcCtD
Nevirapine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000116	0.00103	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000116	0.00102	CbGpPWpGaD
Nevirapine—Pruritus—Doxorubicin—urinary bladder cancer	0.000115	0.0005	CcSEcCtD
Nevirapine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000114	0.00101	CbGpPWpGaD
Nevirapine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000112	0.00099	CbGpPWpGaD
Nevirapine—Vomiting—Epirubicin—urinary bladder cancer	0.000112	0.000485	CcSEcCtD
Nevirapine—Nausea—Methotrexate—urinary bladder cancer	0.000111	0.000485	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000111	0.000483	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000111	0.000981	CbGpPWpGaD
Nevirapine—Rash—Epirubicin—urinary bladder cancer	0.000111	0.000481	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—urinary bladder cancer	0.000111	0.000481	CcSEcCtD
Nevirapine—Headache—Epirubicin—urinary bladder cancer	0.00011	0.000478	CcSEcCtD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000105	0.000925	CbGpPWpGaD
Nevirapine—Nausea—Epirubicin—urinary bladder cancer	0.000104	0.000454	CcSEcCtD
Nevirapine—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000104	0.000917	CbGpPWpGaD
Nevirapine—Vomiting—Doxorubicin—urinary bladder cancer	0.000103	0.000449	CcSEcCtD
Nevirapine—Rash—Doxorubicin—urinary bladder cancer	0.000102	0.000445	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000102	0.000445	CcSEcCtD
Nevirapine—Headache—Doxorubicin—urinary bladder cancer	0.000102	0.000443	CcSEcCtD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000101	0.000894	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	9.96e-05	0.00088	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	9.96e-05	0.00088	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	9.84e-05	0.00087	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NAT1—urinary bladder cancer	9.84e-05	0.00087	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.69e-05	0.000856	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	9.69e-05	0.000856	CbGpPWpGaD
Nevirapine—Nausea—Doxorubicin—urinary bladder cancer	9.65e-05	0.00042	CcSEcCtD
Nevirapine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	9.5e-05	0.00084	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.42e-05	0.000833	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.37e-05	0.000828	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.29e-05	0.000821	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.24e-05	0.000817	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	9e-05	0.000795	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.97e-05	0.000792	CbGpPWpGaD
Nevirapine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	8.73e-05	0.000772	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	8.68e-05	0.000767	CbGpPWpGaD
Nevirapine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.66e-05	0.000765	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.65e-05	0.000764	CbGpPWpGaD
Nevirapine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.61e-05	0.000761	CbGpPWpGaD
Nevirapine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.54e-05	0.000755	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	8.49e-05	0.00075	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	8.49e-05	0.00075	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTZ1—urinary bladder cancer	8.38e-05	0.00074	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	8.19e-05	0.000723	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	8.11e-05	0.000716	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.09e-05	0.000715	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	8.09e-05	0.000715	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	8.05e-05	0.000711	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	8.02e-05	0.000709	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NAT1—urinary bladder cancer	7.94e-05	0.000702	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	7.94e-05	0.000702	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.94e-05	0.000702	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NAT1—urinary bladder cancer	7.76e-05	0.000686	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	7.76e-05	0.000686	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	7.65e-05	0.000676	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	7.46e-05	0.000659	CbGpPWpGaD
Nevirapine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	7.4e-05	0.000654	CbGpPWpGaD
Nevirapine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.3e-05	0.000645	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	7.26e-05	0.000642	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	7.1e-05	0.000627	CbGpPWpGaD
Nevirapine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.82e-05	0.000603	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	6.54e-05	0.000578	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	6.39e-05	0.000565	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.21e-05	0.000549	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	6.18e-05	0.000546	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.13e-05	0.000542	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	6.04e-05	0.000533	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	6.02e-05	0.000532	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—TYMP—urinary bladder cancer	5.96e-05	0.000527	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	5.88e-05	0.00052	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.82e-05	0.000514	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.77e-05	0.00051	CbGpPWpGaD
Nevirapine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.71e-05	0.000505	CbGpPWpGaD
Nevirapine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.63e-05	0.000498	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.52e-05	0.000488	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.52e-05	0.000488	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.47e-05	0.000483	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.47e-05	0.000483	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NAT2—urinary bladder cancer	5.39e-05	0.000477	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.38e-05	0.000476	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	5.05e-05	0.000446	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5e-05	0.000442	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	4.93e-05	0.000436	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—TYMP—urinary bladder cancer	4.81e-05	0.000425	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—TYMP—urinary bladder cancer	4.7e-05	0.000416	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	4.68e-05	0.000413	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	4.68e-05	0.000413	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—RRM2—urinary bladder cancer	4.66e-05	0.000411	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.6e-05	0.000406	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.55e-05	0.000402	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.51e-05	0.000398	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NAT2—urinary bladder cancer	4.35e-05	0.000384	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ENO2—urinary bladder cancer	4.31e-05	0.000381	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	4.31e-05	0.000381	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	4.29e-05	0.000379	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	4.28e-05	0.000378	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.26e-05	0.000376	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NAT2—urinary bladder cancer	4.25e-05	0.000376	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	4.18e-05	0.00037	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	4.18e-05	0.000369	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.15e-05	0.000366	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	3.85e-05	0.00034	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.81e-05	0.000336	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—RRM2—urinary bladder cancer	3.76e-05	0.000332	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—RRM2—urinary bladder cancer	3.67e-05	0.000324	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	3.64e-05	0.000321	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.61e-05	0.000319	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.61e-05	0.000319	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	3.54e-05	0.000313	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ENO2—urinary bladder cancer	3.48e-05	0.000307	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	3.48e-05	0.000307	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NQO1—urinary bladder cancer	3.48e-05	0.000307	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.4e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.4e-05	0.0003	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.37e-05	0.000298	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.34e-05	0.000295	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.32e-05	0.000294	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.32e-05	0.000293	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.3e-05	0.000292	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.3e-05	0.000291	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.18e-05	0.000281	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.02e-05	0.000267	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3e-05	0.000265	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.97e-05	0.000263	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	2.9e-05	0.000256	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.84e-05	0.000251	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.83e-05	0.00025	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.81e-05	0.000248	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.8e-05	0.000248	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.74e-05	0.000242	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.73e-05	0.000242	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.72e-05	0.00024	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—TYMS—urinary bladder cancer	2.69e-05	0.000238	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	2.66e-05	0.000235	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	2.66e-05	0.000235	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.61e-05	0.000231	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000229	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	2.56e-05	0.000226	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	2.55e-05	0.000225	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	2.5e-05	0.000221	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.42e-05	0.000214	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.42e-05	0.000214	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.000212	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.000212	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.38e-05	0.000211	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	2.35e-05	0.000208	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.35e-05	0.000207	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.34e-05	0.000207	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.32e-05	0.000205	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.29e-05	0.000202	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.29e-05	0.000202	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.21e-05	0.000195	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.19e-05	0.000193	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.17e-05	0.000192	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2.15e-05	0.00019	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2.15e-05	0.00019	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.13e-05	0.000188	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.1e-05	0.000186	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.1e-05	0.000186	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.06e-05	0.000182	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.05e-05	0.000181	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.05e-05	0.000181	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.04e-05	0.00018	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.02e-05	0.000179	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.01e-05	0.000178	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.99e-05	0.000176	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.98e-05	0.000175	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.97e-05	0.000175	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.96e-05	0.000173	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.95e-05	0.000172	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.93e-05	0.000171	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.91e-05	0.000169	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.9e-05	0.000168	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.87e-05	0.000166	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.86e-05	0.000164	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.83e-05	0.000162	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.71e-05	0.000151	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000146	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.63e-05	0.000144	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.63e-05	0.000144	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	0.000142	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.6e-05	0.000142	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.58e-05	0.00014	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.58e-05	0.00014	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.56e-05	0.000138	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.54e-05	0.000136	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.53e-05	0.000135	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.51e-05	0.000134	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.51e-05	0.000133	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	1.5e-05	0.000133	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000132	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.49e-05	0.000132	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.49e-05	0.000132	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000131	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000131	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.48e-05	0.000131	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.45e-05	0.000128	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.43e-05	0.000126	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000125	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000124	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.4e-05	0.000123	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	0.000123	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.38e-05	0.000122	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.33e-05	0.000118	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.32e-05	0.000117	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	1.31e-05	0.000116	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000116	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.28e-05	0.000113	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.27e-05	0.000113	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.27e-05	0.000112	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.27e-05	0.000112	CbGpPWpGaD
Nevirapine—CYP2A6—Metabolism—EP300—urinary bladder cancer	1.25e-05	0.00011	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.21e-05	0.000107	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	0.000107	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	0.000105	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.18e-05	0.000105	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	9.88e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.07e-05	9.46e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.06e-05	9.39e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.06e-05	9.38e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.06e-05	9.34e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.03e-05	9.13e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.03e-05	9.09e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	9.01e-05	CbGpPWpGaD
Nevirapine—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.01e-05	8.9e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.88e-06	8.73e-05	CbGpPWpGaD
Nevirapine—CYP3A5—Metabolism—EP300—urinary bladder cancer	9.85e-06	8.7e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.77e-06	8.63e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.77e-06	8.63e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.35e-06	8.26e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.18e-06	8.11e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	9.07e-06	8.01e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	8.71e-06	7.7e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.63e-06	7.63e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	8.42e-06	7.44e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.35e-06	7.38e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	7.34e-06	6.49e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.28e-06	6.43e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	7.13e-06	6.3e-05	CbGpPWpGaD
Nevirapine—CYP2D6—Metabolism—EP300—urinary bladder cancer	7e-06	6.19e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7e-06	6.18e-05	CbGpPWpGaD
Nevirapine—CYP2C9—Metabolism—EP300—urinary bladder cancer	6.94e-06	6.13e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.72e-06	5.94e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	6.22e-06	5.5e-05	CbGpPWpGaD
Nevirapine—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.93e-06	5.24e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.51e-06	4.86e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.8e-06	4.24e-05	CbGpPWpGaD
Nevirapine—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.58e-06	4.05e-05	CbGpPWpGaD
